


























 Cryptococcus neoformans is an opportunistic fungal pathogen that is spread through 
inhalation and predominantly causes disease in immunocompromised patients. The infection 
begins in the lungs as pneumonia and can disseminate into the central nervous system causing a 
fatal brain infection called cryptococcal meningitis. Dendritic cells (DCs) in the respiratory tract 
can phagocytose and kill inhaled C. neoformans in the lysosomal compartment. In addition, DC 
lysosomal extract has anti-cryptococcal activity. A purified lysosomal protease, cathepsin B, 
exhibits significant growth inhibition of Cryptococcus by an unknown mechanism resulting in 
osmotic lysis of the organism. Due to the morphology observed after cathepsin B treatment, we 
hypothesize that the cathepsin B is targeting the fungal cell wall integrity pathway. For these 
studies, we have treated C. neoformans with cathepsin B and have shown that cathepsin B has 
anti-cryptococcal activity. We are currently examining the cell wall integrity pathway 
with/without treatment by Western blot, and are examining the phosphorylation of PKA (the first 
protein in the signaling cascade) to determine if cathepsin B affects this pathway. The minimum 
inhibitory concentration assay of cathepsin B is also being examined in comparison with 
amphotericin B, a common antifungal drug known to inhibit C. neoformans growth. Future 
studies will examine phosphorylation of PKA and additional proteins in the cell wall integrity 
pathway and the effects of cathepsin B on cryptococcal virulence factors to identify additional 






 Cryptococcus neoformans is an opportunistic fungal pathogen that is ubiquitous in nature 
and can predominantly be isolated from soil containing bird guano and rotting wood (Soltani, et 
al., 2013). The infection is typically spread through inhalation of aerosolized organisms. When 
inhaled, C. neoformans can cause severe infection in immunocompromised patients, particularly 
transplant recipients and those with HIV/AIDS (Pappas, et al., 2010; Park, et al., 2009). 
However, healthy individuals are rarely affected. The infection manifests in the lungs causing 
pneumonia, but due to its propensity to invade the central nervous system, it can rapidly 
disseminate into the bloodstream, causing cryptococcal meningitis (Góralska, et al., 2018). This 
clinical manifestation is often fatal in AIDS patients. In AIDS patients alone it is estimated that 
there are over 220,000 cases each year, resulting in over 181,000 deaths (Rajasingham, et al., 
2017). Unfortunately, there are limited treatment options. Drug toxicity and antimicrobial 
resistance are current challenges (Denning & Bromley, 2015). In over 30 years, there have been 
no new antifungal drugs with cryptococcal activity introduced for treatment, highlighting the 
necessity of new antifungal agents targeting Cryptococcus (O'Halloran, et al., 2017).  
           Previous studies have shown that inhaled C. neoformans can be phagocytosed and killed 
by dendritic cells (DCs) in the lysosomal compartment through the endosomal and lysosomal 
pathways (Wozniak & Levitz, 2008). Additionally, it has been shown that DC lysosomal extract 
has significant anti-cryptococcal activity against multiple cryptococcal strains (Hole, et al., 
2012). Cathepsin B is a lysosomal cysteine protease that primarily functions in intracellular 
proteolysis and is also known to be involved in hormone activation and bone turnover (Mort & 
Buttle, 1998). Interestingly, purified cathepsin B was found to inhibit the growth of C. 
neoformans using an unknown non-oxidative mechanism, resulting in the osmotic lysis of the 
fungus. Using scanning electron microscopy and transmission electron microscopy structural 
changes of the cells when treated with cathepsin B show a crescent morphology indicative of cell 
death with a ruptured cell wall but an intact cell membrane (Hole, et al., 2012). Since the 
inhibition of C. neoformans by cathepsin B is concentration-dependent, minimum inhibitory 
concentration (MIC) tests are being conducted to determine the lowest concentration of cathepsin 
B to be used in the following experiments.  
           Recent studies, as well as the morphology of the cells after cathepsin B treatment, suggest 
that the antifungal mechanism may be targeting the cell wall integrity (CWI) pathway. The CWI 
pathway is primarily responsible for the maintenance and biosynthesis of the fungal cell wall 
(Free, 2013). The target of this study is Pkc-1, which is the first protein in the signaling cascade. 
Studies will use western blot analysis to examine the phosphorylation of PKC-1 and additional 
proteins in the signal cascade before and after the treatment of cathepsin B.  
 
MATERIAL & METHODS 
Strains & Media. Cryptococcus. neoformans strain H99 (serotype A) was recovered from a 
15% glycerol stock stored at -80°C prior to use in these experiments. The strain was maintained 
on yeast extract/peptone/dextrose (YPD) agar plates. Yeast cells were grown for 18 hours at 
30°C with shaking in YPD broth. Cells were washed three times with sterile phosphate-buffered 
saline (PBS). Cells were quantified using trypan blue dye exclusion in a hemacytometer. 
 
Incubation of lysosomal extracts with Cryptococcus. Following culture for 18 hours at 30°C, 
organisms were washed 3X with sterile PBS and resuspended in 10mM phosphate buffer with 
2% RPMI, pH 5.5 (phosphate buffer) and adjusted to the concentration needed for the 
experiment. For each well, 50 μl (2.5x105/ml) of Cryptococcus were added to a 96-well plate. 
Phosphate buffer (50 μl) was added to control wells, and 50 μl of lysosomal extract was added to 
the test wells, to a total volume of 100 μl. Plates were then incubated for 24 hours at 37°C. 
Following incubation, organisms were diluted in sterile PBS and plated on YPD agar to 
determine CFU. Killing of Cryptococcus was defined as CFU below the initial inoculum and 
inhibition was defined as CFU below the growth in media alone.  
  
Incubation of purified cathepsin B with Cryptococcus. Purified enzyme killing of 
Cryptococcus was tested using cathepsin B at 50 μg/ml in phosphate buffer with Cryptococcus, 
as described above. 
  
Electron Microscopy. Cryptococcus neoformans strain H99 (serotype A) was incubated with 
cathepsin B and/or calpain as described above for 12 hours. Cells were then fixed with 4% 
formaldehyde and 1% glutaraldehyde and processed for both scanning and transmission electron 
microscopy.  
 
Protein Purification. Proteins were purified from C. neoformans using both the Allprep Fungal 
DNA/RNA/Protein Kit (Qiagen) kit and the Zymo Research Yeast Protein Kit using 
manufacturer’s instructions for Western Blot Analysis. Protein was quantified using the Take3TM 
plate and reading on the Synergy HTX multi-mode plate reader (BioTek, Winooski, VT). 
 
Gel Electrophoresis. Protein samples were combined with Lammeli Sample Buffer and heated 
for 5 mins before loading. A pre-cast 8% mini gel was used in surelock gel and running buffer 
was poured in. Samples and BenchmarkTM pre-stained ladder were loaded in wells and the gel 
was run at 150V for 1 hour. The gel was stained with Coomassie blue to visualize protein bands.  
Western Blot. The membrane transfer was run at 30V for 2 hours and proteins were transferred 
to a PVDF membrane. The membrane was washed in TBST for 5 mins three times. The 
membrane was covered with blocking buffer and incubated for 1 hour on a shaker.  F-actin 
Antibody (NH3)(1:500) invitrogen was diluted in 10mL of blocking buffer and and incubated 
with the membrane for 1 hour on a shaker. The membrane was washed again in TBST. Goat 
anti-mouse IgG (H+L), horseradish peroxidase conjugate (1:10000) invitrogen was diluted in 
10mL of blocking buffer and incubated with the membrane for 1 hour on a shaker. TBST was 
used to wash the membrane. PKA C-alpha Rabbit Antibody and Anti-rabbit IgG, HRP-linked 
antibodies were used at varying concentrations and need further troubleshooting.  
 
Chemiluminescence Imaging.  SuperSignal West Dura Extended Duration Substrate Kit was 
used to detect F-actin on the membrane. 1 ml of each substrate was mixed by inversion and 
allowed to incubate on the membrane for 1 minute before imaging using the Protein Simple 
Fluorochem E (Protein Simple, San Jose, CA).  
 
Minimum Inhibitory Concentration. Minimum Inhibitory Concentration (MIC) assays were 
conducted as described by the Clinical Laboratory Standards Institute (CLSI, 2008). Briefly, in a 
96-well plate, 100μl of media was added to rows 1-11. In row 12, 100μl of Amphotericin B 
(200μg/ml) or cathepsin B (451μg/ml) was added. After adding the drug, 100μl was taken from 
row 12 and added to row 11. This 1:2 dilution was repeated until row 2. 100μl was taken from 
row 2 and discarded, and row 1 remained as media alone (as a growth control row). 100μl of C. 
neoformans was added to every well. The plate was incubated at 35°C for two days. The plate 
was analyzed using the TAKE3TM plate and read on the Synergy HTX multi-mode plate reader 
(BioTek, Winooski, VT). For the Amphotericin B MIC assay, RPMI-MOPS media was used and 
0.5x103/ml of C. neoformans was added to the plate. For the Cathepsin B MIC assay, phosphate 
buffer media (0.1M potassium phosphate, plus 2% RPMI, pH 5.5) was used and 10x107/ml of C. 
neoformans was added to the plate.  
 
RESULTS 
 Anti-cryptococcal activity of DC lysosomal extract and Cathepsin B. Previous 
research concludes that DC lysosomal extract and Cathepsin B exhibit anti-cryptococcal activity 
(Hole, et al., 2012; Wozniak & Levitz, 2008). To confirm these results an in-vitro killing assay 
was performed. Results showed there was significant cryptococcal killing and inhibition of C. 
neoformans when treated with the substances (Figure 1). There was significant killing of the C. 
neoformans when added to DC lysosomal extract with CFU/ml levels close to zero. The purified 
lysosomal protease, cathepsin B (50μg/ml) exhibited significant growth inhibition of C. 
neoformans with CFU/ml levels four times lower than untreated fungi.  
  The results of another study indicated that cathepsin B kills the fungus by an unknown 
mechanism using osmotic lysis (Hole, et al., 2012). Electron microscopy of C. neoformans 
treated with Cathepsin B revealed a ruptured cell wall and an intact cell membrane (Figure 2). 
The published information regarding the organization of the C. neoformans cell wall reveals 
there are no substrates for cathepsin B to bind (Free, 2013, p.33-82). The cathepsin B may be 
targeting the cell wall integrity pathway resulting in osmotic lysis of the cell (Figure 3). Because 
of the nature of the cell wall in maintaining osmolality, in addition to the CWI pathway being a 
common antifungal target, it is likely that the cathepsin B mechanism of action involves the CWI 
pathway specifically the mitogen-activated protein (MAP) kinase cascade (Levin, 2005). The 

















Figure 1. Anti-cryptococcal Activity of DC Lysosomal 
Extract and Lysosomal Protein Cathepsin B. 
Cryptococcus is killed by the lysosomal extracts. Purified 
lysosomal enzyme cathepsin B significantly inhibits the 
growth of Cryptococcus at 50 μg/ml concentration. Data 
shown are means (+/-) SEM for 3 independent 
experiments.  
Figure 2. Cathepsin B Structural Effects on 
Cryptococcus. Cathepsin B causes structural changes 
to Cryptococcus following 12-hr incubation by (A) 




Figure 3. Fungal Cell Wall Integrity Pathway. 
Diagram of the CWI MAP kinase cascade.  
























Hole, et al., 2012 
 Protein Purification using Zymo Research Protein Kit is needed for analysis of 
proteins in Western Blot. Two protein purification kits, Allprep Fungal DNA/RNA/Protein Kit 
(Qiagen) kit and the Zymo Research Yeast Protein Kit, were compared in order to determine 
which would produce visible bands using the least amount of cells. C. neoformans proteins from 
different cell amounts (1million, 3 million,10 million, and 30 million) were purified from the 
Qiagen kit and quantified (Table 1). The proteins were separated using gel electrophoresis and 
analyzed through coomassie staining and western blot (Figure 4A and 4B). C. neoformans 
proteins from higher cell amounts (10 million, 15 million, 20 million, and 25 million) were 
purified from the Zymo kit and analyzed similar to the proteins purified from the Qiagen kit, 
excluding coomassie staining (Table 2 and Figure 5A). The results show the purified protein 
amounts using the Zymo kit was higher than the amounts using the Qiagen kit. Using the Zymo 
kit, the 42kDa F-actin band can be visualized at all concentrations tested. In comparison, using 













280 260 260/280 µg/mL 
1 SPL1 1x106Cells B2 0.046 0.049 0.042 0.001 0.002 1.875 16.444 
1 SPL2 3x106 Cells C2 0.043 0.046 0.04 0.001 0.001 2 12.479 
1 SPL3 10x106 Cells D2 0.047 0.049 0.04 0.004 0.004 0.837 89.156 
1 SPL4 30x106Cells E2 0.066 0.061 0.041 0.024 0.016 0.659 474.316 
1 SPL5 BSA F2 0.106 0.087 0.039 0.066 0.045 0.684 1319.86 
Table 1. Quantification of proteins purified from Qiagen kit. The quantification of Cryptococcus 




















280 260 260/280 µg/mL 
1 SPL1 10x106 Cells  B2 0.173 0.21 0.089 0.068 0.1 1.469 1366.906 
1 SPL2 15x106 Cells  C2 0.238 0.289 0.12 0.105 0.152 1.45 2098.586 
1 SPL3 20x106 Cells  D2 0.366 0.448 0.187 0.168 0.248 1.478 3350.612 
1 SPL4 25x106 Cells  E2 0.467 0.577 0.243 0.214 0.323 1.506 4283.347 
Figure 4. Analysis of Qiagen Protein Purification. (A) Coomassie Stain of gel indicates that protein bands can 
be visualized from 30 million cells. Bands are faintly seen from 10 million cell and cannot be seen at all from 3 
million and 1 million cells. (B) Through western blot analysis, 42kDa F-actin was only identified at the 
concentration of 30 million cells.  
Table 2. Quantification of proteins purified from Zymo kit. The quantification of Cryptococcus proteins purified 












 Un-phosphorylated PKA-C antibody can not be visualized at tested concentrations. 
To begin experiments to determine if the cell wall integrity pathway of C. neoformans is 
activated when treated with cathepsin B, control experiments using untreated fungi must be 
performed and antibody concentration must be optimized. Three different antibody concentration 
combinations have been tested: primary antibody concentration of 1:1000 and secondary 
antibody concentration of 1:1000, primary antibody concentration of 1:500 and secondary 
antibody concentration of 1:1000, and primary antibody concentration of 1:500 and secondary 
antibody concentration of 1:500. The 42kDa PKA-C antibody was not identified in any of the 
three combination (Figure 6-8). 
Figure 5. Analysis of Zymo Protein Purification. Quantification of purified Cryptococcus proteins. 


















 Minimum Inhibitory Concentration Assay. A MIC assay was performed on known 
antifungal drug Amphotericin B. The MIC was found to be in a normal range of 1.56-3.125 
Figure 7. Imaging of western blot using primary antibody 
concentration of 1:500 and secondary antibody 
concentration of 1:1000. 42KDa PKA-C was not 
identified at these antibody concentrations. 
Figure 6. Imaging of western blot using primary antibody 
concentration of 1:1000 and secondary antibody 
concentration of 1:1000. 42KDa PKA-C was not identified 
at these antibody concentrations.  
Figure 8. Imaging of western blot using primary antibody 
concentration of 1:500 and secondary antibody 
concentration of 1:500. 42KDa PKA-C was not identified 





µg/ml (data not shown). Another assay was performed using cathepsin B and 10 million 
cryptococcal cells (the minimum number identified by Western Blot for F-actin, Figure 5) 
though there was no MIC due to the concentration of drug not starting high enough to inhibit the 
Cryptococcus (Table 3). Additional MIC assays will need to be performed using cathepsin B 










 There are many modes of action of antifungal components but the increased incidence of 
resistance has led to the exploration of new drug targets. New approaches to antifungal drug 
development include targeting the components in the fungal cell wall pathways (Hasim & 
Coleman, 2019). Cathepsin B has anti-cryptococcal activity but the mechanism of this activity is 
still unknown. The structural changes of cryptococcal cells when treated with cathepsin B 
suggests interferences with the cell wall pointing to the targeting of the cell wall integrity 
pathway.  
 These preliminary studies contain results to be used in future experiments. Cathepsin B 
was confirmed to have anti-fungal activity against C. neoformans. This anti-cryptococcal 
  1 2 3 4 5 6 7 8 9 10 11 12 
A 0.765 0.76 0.762 0.76 0.769 0.754 0.754 0.753 0.756 0.775 0.786 0.743 
B 0.773 0.765 0.756 0.752 0.753 0.759 0.754 0.75 0.761 0.76 0.776 0.701 
Table 3: MIC assay results for cathepsin B. There was no inhibition of Cryptococcus in any 
of the wells.  
mechanism is in the process of being identified by western blot analysis. The Zymo protein kit 
was found to purify more proteins than the Qiagen protein kit, making it the best option for the 
western blot experiments. The bands binding to the un-phosphorylated PKA-C antibody should 
be visualized in western bot analysis of untreated Cryptococcus since the pathway should not be 
activated and there should be un-phosphorylated PKA-C proteins. The inability to visualize the 
antibody could be due to the concentration conditions or a higher number of Cryptococcus cells 
need to be purified. Finding the MIC of cathepsin B could help in determining how much to 
scale up the cell count in regards to the on-hand access of cathepsin B.  
 Future studies will include testing other antibody concentration combinations to visualize 
the un-phosphorylated PKA-C band. Once optimization is complete, both the phosphorylated 
and un-phosphorylated PKA-C antibody will need to be analyzed using western blots analysis of 
cryptococcal cells treated with and without cathepsin B to determine if the cell wall integrity 
pathway is being activated by cathepsin B. If the phosphorylated PKA-C band is visualized in 
the treated cells, the next proteins in the CWI MAP kinase cascade will need to be analyzed such 
as Bck1, Mkk2, Mkk1, and Mpk1. To determine the minimum concentration of cathepsin B 
needed to inhibit Cryptococcus to use in future experiments. MIC assays will need to be 
performed starting at a higher concentration. These future studies will allow us to determine the 
role of the CWI pathway in the anti-cryptococcal activity of cathepsin B.  
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